IL142864D0 - Compositions and methods for producing vascular occlusion - Google Patents

Compositions and methods for producing vascular occlusion

Info

Publication number
IL142864D0
IL142864D0 IL14286499A IL14286499A IL142864D0 IL 142864 D0 IL142864 D0 IL 142864D0 IL 14286499 A IL14286499 A IL 14286499A IL 14286499 A IL14286499 A IL 14286499A IL 142864 D0 IL142864 D0 IL 142864D0
Authority
IL
Israel
Prior art keywords
compositions
methods
vascular occlusion
producing vascular
producing
Prior art date
Application number
IL14286499A
Original Assignee
Novolytics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US10812998P priority Critical
Application filed by Novolytics Inc filed Critical Novolytics Inc
Priority to PCT/IB1999/001809 priority patent/WO2000029029A1/en
Publication of IL142864D0 publication Critical patent/IL142864D0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727Heparin; Heparan
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
IL14286499A 1998-11-12 1999-11-10 Compositions and methods for producing vascular occlusion IL142864D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10812998P true 1998-11-12 1998-11-12
PCT/IB1999/001809 WO2000029029A1 (en) 1998-11-12 1999-11-10 Compositions and methods for producing vascular occlusion

Publications (1)

Publication Number Publication Date
IL142864D0 true IL142864D0 (en) 2002-03-10

Family

ID=22320484

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14286499A IL142864D0 (en) 1998-11-12 1999-11-10 Compositions and methods for producing vascular occlusion
IL142864A IL142864A (en) 1998-11-12 2001-04-30 Compositions for producing vascular occlusion

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL142864A IL142864A (en) 1998-11-12 2001-04-30 Compositions for producing vascular occlusion

Country Status (10)

Country Link
US (4) US6887474B1 (en)
EP (1) EP1131106B1 (en)
JP (1) JP2002529521A (en)
AT (1) AT434447T (en)
AU (1) AU773174B2 (en)
CA (1) CA2348781A1 (en)
DE (1) DE69941031D1 (en)
IL (2) IL142864D0 (en)
RU (1) RU2227752C2 (en)
WO (1) WO2000029029A1 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749853B1 (en) * 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US6818213B1 (en) * 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
AT230614T (en) * 1998-07-13 2003-01-15 Univ Texas Cancer treatment with aminophospholipids binding, therapeutic conjugates
IL142864D0 (en) * 1998-11-12 2002-03-10 Novolytics Inc Compositions and methods for producing vascular occlusion
AT410119T (en) 1998-12-01 2008-10-15 Univ Washington A device for intravascular embolization
AU2002334266B2 (en) * 2001-09-12 2008-06-19 Virexx Medical Corporation Vascular occlusion solid-phase agent with immobilised platelet binding agent
TW200303919A (en) 2001-12-05 2003-09-16 Hiroyuki Ohno Cytotoxic protein and the use
CA2469087A1 (en) * 2001-12-07 2003-06-12 Virexx Medical Corp. Compositions and methods for producing vascular occlusion
AU2003249641B2 (en) 2002-05-16 2009-08-20 Glycomimetics, Inc. Compounds and methods for inhibiting selectin-mediated function
US20040180812A1 (en) * 2002-12-13 2004-09-16 Technology Center Methods of treating and preventing proliferative disease
FR2851211B1 (en) 2003-02-19 2006-01-13 Faurecia Sieges Automobile folding seat and vehicle comprising such a seat
US8367669B2 (en) * 2005-06-15 2013-02-05 Vanderbilt University Inhibitors of hemeprotein-catalyzed lipid peroxidation
US9133212B1 (en) 2005-06-15 2015-09-15 Vanderbilt University Inhibitors of hemeprotein-catalyzed lipid peroxidation
WO2006002073A2 (en) * 2004-06-15 2006-01-05 Vanderbilt University Method for preventing heme-induced lipid peroxidation
US9155764B1 (en) 2004-12-07 2015-10-13 University Of Miami Expanded utility of red-cell derived microparticles (RMP) for treatment of bleeding
WO2006062945A2 (en) * 2004-12-07 2006-06-15 University Of Miami Cell-derived microparticles as hemostatic agents for control of hemorrhage and treatment of bleeding disorders
AT528311T (en) 2005-08-09 2011-10-15 Glycomimetics Inc Glycomimetische inhibitors of the pa-il-lectin, PA-IIL lectin or both lectins from Pseudomonas
PL2264043T3 (en) 2005-09-02 2018-04-30 Glycomimetics, Inc. Heterobifunctional pan-selectin inhibitors
US20070178104A1 (en) * 2006-01-31 2007-08-02 Awdalla Essam T Methods and means for treating solid tumors
WO2007147127A2 (en) * 2006-06-15 2007-12-21 Cook Incorporated Methods, systems, and devices for the delivery of endoluminal prostheses
WO2008060378A2 (en) 2006-10-12 2008-05-22 Glycomimetics, Inc. Glycomimetic replacements for hexoses and n-acetyl hexosamines
US7879793B2 (en) 2006-10-18 2011-02-01 Baylor College Of Medicine Treatment of medical condition with A2 domain of von willebrand factor
NZ598863A (en) 2007-02-09 2013-11-29 Glycomimetics Inc Methods of use of glycomimetics with replacements for hexoses and n-acetyl hexosamines
US8372427B2 (en) 2007-03-05 2013-02-12 Abbott Cardiovascular Systems Inc. Therapeutic composition with enhanced endothelium targeting
US8039442B2 (en) 2007-07-18 2011-10-18 Glycomimetics, Inc. Compounds and methods for treatment of sickle cell disease or complications associated therewith
US8617820B2 (en) * 2007-08-28 2013-12-31 Ortho-Clinical Diagnostics, Inc. Use of glycosaminoglycans to reduce non-specific binding in immunoassays
WO2009036250A1 (en) * 2007-09-12 2009-03-19 Cook Incorporated Enhanced remodelable materials for occluding bodily vessels and related methods and systems
CN102089006B (en) * 2007-11-26 2013-08-28 Im生物技术有限公司 Compositions and methods for producing vascular occlusion using solid-phase platelet binding agent
JP5471447B2 (en) * 2007-12-25 2014-04-16 国立大学法人山口大学 Drug delivery system
US8895510B2 (en) 2008-04-08 2014-11-25 Glycomimetics, Inc. Pan-selectin inhibitor with enhanced pharmacokinetic activity
CN102088983B (en) 2008-06-13 2013-01-30 糖模拟物有限公司 Treatment of cancers of the blood using selected glycomimetic compounds
US20170204191A1 (en) * 2008-10-06 2017-07-20 Cynthia C. Bamdad Muc1* antibodies
NZ595484A (en) * 2009-04-17 2014-04-30 Niiki Pharma Inc Method of treating hepatocellular carcinoma
US8410066B2 (en) 2009-05-01 2013-04-02 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectins and CXCR4 chemokine receptors
US9044454B2 (en) * 2010-03-10 2015-06-02 Northwestern University Regulation of microvasculature occlusion
US8921328B2 (en) 2010-09-14 2014-12-30 Glycomimetics, Inc. E-selectin antagonists
JP2017526740A (en) * 2014-08-08 2017-09-14 ヴィンディコ ナノバイオテクノロジー, エルエルシー Compositions and methods for inducing nanoparticle-mediated microvascular embolization of tumor
JP2014531444A (en) * 2011-09-15 2014-11-27 オムセラ・ファーマシューティカルズ・インコーポレイテッド Or treating resistance to antiplatelet therapy, or reverse, inhibit or methods and compositions for preventing
NZ627068A (en) 2011-12-22 2016-09-30 Glycomimetics Inc E-selectin antagonist compounds, compositions, and methods of use
EP2928476B1 (en) 2012-12-07 2018-02-14 GlycoMimetics, Inc. Compounds, compositions and methods using e-selectin antagonists for mobilization of hematopoietic cells
KR101552138B1 (en) * 2012-12-26 2015-09-10 국립암센터 Novel composition for labelling cancer lesion
WO2015154057A1 (en) * 2014-04-04 2015-10-08 Nhan Tran Methods for treating cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093399A (en) * 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
MX9700312A (en) * 1994-07-11 1997-07-31 Univ Texas Methods and compositions for the specific coagulation of vasculature.
US5763199A (en) * 1994-09-29 1998-06-09 Mount Sinai School Of Medicine Of The City University Of New York Platelet blockade assay
JPH08333400A (en) * 1995-06-09 1996-12-17 Ajinomoto Co Inc Fused protein having antithrombogenic activity and its production
CA2239303A1 (en) * 1995-12-22 1997-07-03 Somatogen, Inc. Globins containing binding domains
KR100565883B1 (en) * 1997-01-22 2006-03-31 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 Tissue factor methods and compositions for coagulation and tumor treatment
IL142864D0 (en) * 1998-11-12 2002-03-10 Novolytics Inc Compositions and methods for producing vascular occlusion
AU2002334266B2 (en) * 2001-09-12 2008-06-19 Virexx Medical Corporation Vascular occlusion solid-phase agent with immobilised platelet binding agent

Also Published As

Publication number Publication date
WO2000029029A1 (en) 2000-05-25
CA2348781A1 (en) 2000-05-25
US7947282B2 (en) 2011-05-24
DE69941031D1 (en) 2009-08-06
AU773174B2 (en) 2004-05-20
EP1131106A1 (en) 2001-09-12
US7390488B2 (en) 2008-06-24
IL142864A (en) 2007-09-20
EP1131106B1 (en) 2009-06-24
AU1171600A (en) 2000-06-05
US6887474B1 (en) 2005-05-03
AT434447T (en) 2009-07-15
US20050287145A1 (en) 2005-12-29
WO2000029029A9 (en) 2000-11-02
US20070098724A1 (en) 2007-05-03
US20020168366A1 (en) 2002-11-14
RU2227752C2 (en) 2004-04-27
JP2002529521A (en) 2002-09-10

Similar Documents

Publication Publication Date Title
DE69942584D1 (en) Stent
DE69924706D1 (en) Stent
EP1157707B8 (en) Method and composition for deforming soft tissues
GB2331015B (en) Therapeutic methods and compositions involving isoflavones
DE69934425D1 (en) Thrombopoietin substitute
GB2347685B (en) NiTi-based medical guidewire and method of producing the same
AU764797C (en) Apparatus and method for vascular embolization
GB9900334D0 (en) Tricylic vascular damaging agents
ZA9809272B (en) Method for making soft tissue
GB9714249D0 (en) Vascular damaging agents
DE60039711D1 (en) Hydromorphinone and hydrocodeinone compositions and methods for their synthesis
AUPQ419099A0 (en) Novel compositions and methods
ZA200300597B (en) Composition and method for the repair and regeneration of cartilage and other tissues.
AU9154198A (en) Metallic implant which is degradable in vivo
AUPP583198A0 (en) Mousse composition
AU9094301A (en) Method for preparing graft copolymers and compositions produced therefrom
EP0704217A3 (en) Method for vascular embolization and vascular embolizing agent
GB9917982D0 (en) Compositions
EP0957903A4 (en) Pharmaceutical compositions and methods
PL344863A1 (en) Improved in vivo
AU2480499A (en) Calcification-resistant medical articles
AU3987401A (en) Shaped particle and composition for bone deficiency and method of making the particle
AU1837800A (en) Compositions and methods for whitening teeth
EP1100454A4 (en) Pharmaceutical compositions and methods for managing skin conditions
AU7373700A (en) Vascular closure

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed